UBS moved Tesla to Neutral from Sell and kept its price target at $352, easing one of the harsher calls on the stock even as Wall Street kept wrestling with the company’s outlook. The bank said current share levels more evenly balance Tesla’s near-term demand challenges and investment period with its long-term physical AI opportunity.
The change matters because Tesla has been under pressure as investors debate how much patience to give the company while it works through sales weakness and spending needs. That debate is captured in the linked report, Tsla Stock Falls as Tesla Delivery Miss Deepens Investor Patience Test, and UBS’ move suggests the stock may already reflect some of that strain.
UBS did not stand alone in reshaping its view of automakers and adjacent names on the same day. It also upgraded Ford to Buy from Neutral with an unchanged target of $15, while Deutsche Bank lifted General Motors to Buy from Hold and raised its target to $90 from $83. In the same wave of research changes, Argus initiated coverage of AppLovin with a Buy rating and a $520 price target.
The broader batch of calls came in a roundup of Wall Street research compiled by The Fly, and it cut in several directions at once. Seaport Research upgraded Crocs to Buy from Neutral with a $135 target and also lifted Birkenstock and VF Corp. to Buy from Neutral, while Jefferies upgraded Bloom Energy to Hold from Underperform and set a $187 target, up from $97. Piper Sandler raised Biogen to Overweight from Neutral with a $214 target, but cut Monday.com to Neutral from Overweight with an $85 target, down from $100, and downgraded Asana to Neutral from Overweight with a $7 target, down from $9.
Elsewhere, Craig-Hallum downgraded Fastly to Hold from Buy with a $24 target. Barclays cut Revvity to Equal Weight from Overweight with a $95 target, down from $118, and lowered Qiagen to Equal Weight from Overweight with a $44 target, down from $58. BofA downgraded Omega Healthcare to Underperform from Neutral with a $46 target, down from $52, while BTIG initiated Mondelez with a Buy rating and a $70 target. The pattern is familiar on a busy research day: a few names get a clearer path higher, others get pulled back, and Tesla sits near the center of the market’s argument over what comes next.
